To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Cerebrospinal fluid bioma… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis.

Journal article
Authors Lenka Novakova
Markus Axelsson
Mohsen Khademi
Henrik Zetterberg
Kaj Blennow
Clas Malmeström
Fredrik Piehl
Thomas Olsson
Jan Lycke
Published in Multiple sclerosis (Houndmills, Basingstoke, England)
Volume 23
Issue 1
Pages 62-71
ISSN 1477-0970
Publication year 2017
Published at Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
Institute of Neuroscience and Physiology, Department of Clinical Neuroscience
Pages 62-71
Language en
Subject categories Neurochemistry


The disease-modifying therapies (DMTs) in relapsing-remitting multiple sclerosis (RRMS) vary in their mode of action and when therapies are changed, the consequences on inflammatory and degenerative processes are largely unknown.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?